Parexel - Revision history

Ultra 348 at 22:18, 2 November 2024

2024-11-02T22:18:50Z

← Previous revision		Revision as of 22:18, 2 November 2024
Line 43:		Line 43:
	**''LOGOS GmbH'', a provider of regulatory services to pharmaceutical manufacturers, for $3.9 million in own common stock.<ref>{{Cite news\|url=https://www.wsj.com/articles/SB8888824026187500\|title=Parexel Pays $148 Million For Three European Firms\|last=Bulkeley\|first=William M.\|date=1998-03-03\|newspaper=[[The Wall Street Journal]]\|issn=0099-9660\|access-date=2016-12-25}}</ref>		**''LOGOS GmbH'', a provider of regulatory services to pharmaceutical manufacturers, for $3.9 million in own common stock.<ref>{{Cite news\|url=https://www.wsj.com/articles/SB8888824026187500\|title=Parexel Pays $148 Million For Three European Firms\|last=Bulkeley\|first=William M.\|date=1998-03-03\|newspaper=[[The Wall Street Journal]]\|issn=0099-9660\|access-date=2016-12-25}}</ref>
	* March 1999: Parexel acquires ''Groupe PharMedicom S.A.'', a French provider of post-regulatory services to pharmaceutical manufacturers, based in [[Paris]] and [[Orléans]] and employing approximately 70 people, in exchange for approximately 199,600 shares of the company's common stock.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-groupe-pharmedicom-73816747.html\|title=PAREXEL Acquires Groupe Pharmedicom\|date=1999-04-01\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>		* March 1999: Parexel acquires ''Groupe PharMedicom S.A.'', a French provider of post-regulatory services to pharmaceutical manufacturers, based in [[Paris]] and [[Orléans]] and employing approximately 70 people, in exchange for approximately 199,600 shares of the company's common stock.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-groupe-pharmedicom-73816747.html\|title=PAREXEL Acquires Groupe Pharmedicom\|date=1999-04-01\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>
	* April 1999: [[~~Covance Inc.~~]] announced it would acquire ~~its competitor~~ Parexel for $612.7 million in stock ~~and combine the two drug research and development companies under the name ''Covance Parexel Inc.'',~~<ref>{{Cite ~~web~~\|url=https://www.nytimes.com/1999/04/30/business/company-news-covance-says-it-is-acquiring-parexel-for-612-million.html\|title=COVANCE SAYS IT IS ACQUIRING PAREXEL FOR $612 MILLION\|~~date=1999-04-30\|website~~=[[The New York Times]]\|~~access-~~date=~~2016-12~~-25}}</ref> ~~only to call off~~ the agreement two months later.<ref>{{Cite web\|url=https://money.cnn.com/1999/06/25/deals/covance/\|title=Covance, Parexel part\|date=1999-06-25\|website=[[CNNMoney]]\|access-date=2016-12-25}}</ref>		* April 1999: Covance (now [[Fortea]]) announced it would acquire Parexel for $612.7 million in stock;<ref>{{Cite news \|url=https://www.nytimes.com/1999/04/30/business/company-news-covance-says-it-is-acquiring-parexel-for-612-million.html\|title=COVANCE SAYS IT IS ACQUIRING PAREXEL FOR $612 MILLION \|work=[[The New York Times]] \|date=April 30, 1999 \| url-access=limited}}</ref> however, the agreement was terminated two months later.<ref>{{Cite web\|url=https://money.cnn.com/1999/06/25/deals/covance/\|title=Covance, Parexel part\|date=1999-06-25\|website=[[CNNMoney]]\|access-date=2016-12-25}}</ref>
	* September 1999: Parexel acquires ''CEMAF S.A.'', a Phase I clinical research and bioanalytical laboratory located in [[Poitiers, France]] for an initial cash payment of approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-the-phase-i-clinical-research-business-and-bioanalytical-laboratory-of-cemaf-sa-74407922.html\|title=PAREXEL Acquires the Phase I Clinical Research Business And Bioanalytical Laboratory of CEMAF S.A.\|date=1999-09-15\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>		* September 1999: Parexel acquires ''CEMAF S.A.'', a Phase I clinical research and bioanalytical laboratory located in [[Poitiers, France]] for an initial cash payment of approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-the-phase-i-clinical-research-business-and-bioanalytical-laboratory-of-cemaf-sa-74407922.html\|title=PAREXEL Acquires the Phase I Clinical Research Business And Bioanalytical Laboratory of CEMAF S.A.\|date=1999-09-15\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>
	* September 2000: Parexel acquires a majority interest in ''FARMOVS'', a clinical pharmacology research business and bioanalytical laboratory located in [[Bloemfontein, South Africa]] for approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-majority-interest-in-clinical-pharmacology-research-business-and-bioanalytical-laboratory-in-south-africa-74981577.html\|title=PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa\|date=2000-10-16\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref> A few weeks later the company acquired a clinical pharmacology unit located in [[Northwick Park Hospital]] in [[Harrow (UK Parliament constituency)\|Harrow, U.K.]] from British pharmaceutical company [[GlaxoWellcome Inc.]]<ref>{{Cite web\|url=http://www.drugdiscoveryonline.com/doc/parexel-acquires-glaxos-uk-pharmacology-unit-0001\|title=Parexel acquires Glaxo's UK pharmacology unit\|date=2000-10-04\|website=www.drugdiscoveryonline.com\|access-date=2016-12-25}}</ref>		* September 2000: Parexel acquires a majority interest in ''FARMOVS'', a clinical pharmacology research business and bioanalytical laboratory located in [[Bloemfontein, South Africa]] for approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-majority-interest-in-clinical-pharmacology-research-business-and-bioanalytical-laboratory-in-south-africa-74981577.html\|title=PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa\|date=2000-10-16\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref> A few weeks later the company acquired a clinical pharmacology unit located in [[Northwick Park Hospital]] in [[Harrow (UK Parliament constituency)\|Harrow, U.K.]] from British pharmaceutical company [[GlaxoWellcome Inc.]]<ref>{{Cite web\|url=http://www.drugdiscoveryonline.com/doc/parexel-acquires-glaxos-uk-pharmacology-unit-0001\|title=Parexel acquires Glaxo's UK pharmacology unit\|date=2000-10-04\|website=www.drugdiscoveryonline.com\|access-date=2016-12-25}}</ref>

WiinterU at 13:38, 10 August 2024

2024-08-10T13:38:59Z

← Previous revision		Revision as of 13:38, 10 August 2024
Line 6:		Line 6:
	\| type = [[Privately held company\|Private]]		\| type = [[Privately held company\|Private]]
	\| traded_as = {{NASDAQ was\|PRXL}}		\| traded_as = {{NASDAQ was\|PRXL}}
	\| key_people = Peyton Howell ([[Chief executive officer\|CEO]]		\| key_people = Peyton Howell ([[Chief executive officer\|CEO]])
	\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]		\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]
	\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting		\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting

WiinterU at 13:38, 10 August 2024

2024-08-10T13:38:17Z

← Previous revision		Revision as of 13:38, 10 August 2024
Line 5:		Line 5:
	\| logo_caption =		\| logo_caption =
	\| type = [[Privately held company\|Private]]		\| type = [[Privately held company\|Private]]
			\| traded_as = {{NASDAQ was\|PRXL}}
	\| key_people = ~~CEO:~~ Peyton Howell		\| key_people = Peyton Howell ([[Chief executive officer\|CEO]]
	\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]		\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]
	\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting		\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting
	\| num_employees = 18,900 <ref>{{Cite web\|url=https://www.parexel.com/company--Number-of-Employees\|title=PAREXEL – Our Company\|accessdate=29 March 2023}}</ref>		\| num_employees = 18,900 <ref>{{Cite web\|url=https://www.parexel.com/company--Number-of-Employees\|title=PAREXEL – Our Company\|accessdate=29 March 2023}}</ref>
	\| foundation = 1982		\| foundation = {{start date and age\|1982}}
	\| location = [[Durham, North Carolina]], U.S.		\| location = [[Durham, North Carolina]], U.S.
	[[Newton, Massachusetts]], U.S.		[[Newton, Massachusetts]], U.S.

Smjg: restore maintenance template removed without resolution

2024-07-20T10:33:18Z

restore maintenance template removed without resolution

← Previous revision		Revision as of 10:33, 20 July 2024
Line 67:		Line 67:
	* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>		* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>
	* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />		* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />
	* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[Calyx (clinical research company)\|Calyx]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>		* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[Calyx (clinical research company)\|Calyx]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>{{Primary source inline\|date=June 2023}}
	* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />		* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />

Bigcount: Updated the CEO to reflect change on 15 May 2024

2024-06-06T10:38:00Z

Updated the CEO to reflect change on 15 May 2024

← Previous revision		Revision as of 10:38, 6 June 2024
Line 5:		Line 5:
	\| logo_caption =		\| logo_caption =
	\| type = [[Privately held company\|Private]]		\| type = [[Privately held company\|Private]]
	\| key_people = CEO: ~~Jamie~~ ~~Macdonald~~		\| key_people = CEO: Peyton Howell
	\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]		\| industry = [[Clinical research organization]]s<br />[[Pharmaceutical]]
	\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting		\| services = [[clinical trial]] management, data management, medical writing, [[biostatistics]], [[pharmacovigilance]], regulatory consulting

Smjg: /* Acquisition history */ it's called Calyx, not CALYX

2024-02-26T10:29:24Z

Acquisition history: it's called Calyx, not CALYX

← Previous revision		Revision as of 10:29, 26 February 2024
Line 67:		Line 67:
	* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>		* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>
	* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />		* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />
	* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[~~CALYX~~ (~~Company~~)\|~~CALYX~~]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>		* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[Calyx (clinical research company)\|Calyx]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>
	* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />		* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />

Kku: link lead management

2024-02-12T11:01:35Z

link lead management

← Previous revision		Revision as of 11:01, 12 February 2024
Line 50:		Line 50:
	* January 2003: Parexel acquires ''FWPS Group Limited'', a provider of software for clinical trial management systems in [[Birmingham, UK]], for approximately $11.9 million in cash and shares.<ref name="Form10k_2003">{{cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013503004856/b47766pie10vk.txt\|title=ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES\|date=2003-09-15\|website=PAREXEL Form 10-K (2003)\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>		* January 2003: Parexel acquires ''FWPS Group Limited'', a provider of software for clinical trial management systems in [[Birmingham, UK]], for approximately $11.9 million in cash and shares.<ref name="Form10k_2003">{{cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013503004856/b47766pie10vk.txt\|title=ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES\|date=2003-09-15\|website=PAREXEL Form 10-K (2003)\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>
	* March 2004: Parexel buys the remaining majority of outstanding shares of ''3Clinical Research AG'', a clinical research organization with expertise in Phase I and Phase IIa Proof-Of-Concept studies in [[Berlin, Germany]], for $11.7 million in cash.<ref name="Form10k_2005">{{Cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013505005299/b55585pie10vk.txt\|title=NOTE 18. SUBSEQUENT EVENTS\|date=2005-09-08\|website=Parexel Form 10-K 2005\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>		* March 2004: Parexel buys the remaining majority of outstanding shares of ''3Clinical Research AG'', a clinical research organization with expertise in Phase I and Phase IIa Proof-Of-Concept studies in [[Berlin, Germany]], for $11.7 million in cash.<ref name="Form10k_2005">{{Cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013505005299/b55585pie10vk.txt\|title=NOTE 18. SUBSEQUENT EVENTS\|date=2005-09-08\|website=Parexel Form 10-K 2005\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>
	* October 2004: Parexel acquires ''Integrated Marketing Concepts'' (IMC), a privately held company based in [[Whitehall Township, Pennsylvania\|Whitehall, PA]], provider of professional marketing and communication services specialized in clinical trial [[patient recruitment]] and retention, sales lead management, teleservices, call center services, fulfillment, focus group and database management, and market research.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2004/10/parexel-acquires-marketing-firm.html\|title=Parexel acquires marketing firm\|date=2004-10-04\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>		* October 2004: Parexel acquires ''Integrated Marketing Concepts'' (IMC), a privately held company based in [[Whitehall Township, Pennsylvania\|Whitehall, PA]], provider of professional marketing and communication services specialized in clinical trial [[patient recruitment]] and retention, sales [[lead management]], teleservices, call center services, fulfillment, focus group and database management, and market research.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2004/10/parexel-acquires-marketing-firm.html\|title=Parexel acquires marketing firm\|date=2004-10-04\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>
	* July 2005: Parexel acquires ''Qdot Pharma'', a Phase I and IIa Proof of Concept clinical pharmacology business located in [[George, South Africa]] for approximately $3.0 million plus additional payments of up to approximately $3.0 million in contingent purchase price if Qdot achieves certain established financial targets through September 28, 2008.<ref name="Form10k_2005" />		* July 2005: Parexel acquires ''Qdot Pharma'', a Phase I and IIa Proof of Concept clinical pharmacology business located in [[George, South Africa]] for approximately $3.0 million plus additional payments of up to approximately $3.0 million in contingent purchase price if Qdot achieves certain established financial targets through September 28, 2008.<ref name="Form10k_2005" />
	* August 2005: Parexel buys the remaining 2.2% of its information technology subsidiary ''Perceptive Informatics Inc.'', for $4.8 million in cash.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2005/08/parexel-buys-out-remaining-minority-interest.html\|title=Parexel buys out remaining minority interest in Perceptive Informatics\|date=2005-08-22\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>		* August 2005: Parexel buys the remaining 2.2% of its information technology subsidiary ''Perceptive Informatics Inc.'', for $4.8 million in cash.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2005/08/parexel-buys-out-remaining-minority-interest.html\|title=Parexel buys out remaining minority interest in Perceptive Informatics\|date=2005-08-22\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>

WhinyTheYounger: Removing claim on top 50 companies — source is dead and the underlying text is suspect/promotional. (Archived source also dead). Could not further verify with non-primary sources.

2024-01-31T20:18:18Z

Removing claim on top 50 companies — source is dead and the underlying text is suspect/promotional. (Archived source also dead). Could not further verify with non-primary sources.

← Previous revision		Revision as of 20:18, 31 January 2024
Line 16:		Line 16:
	\| website = {{URL\|parexel.com}}		\| website = {{URL\|parexel.com}}
	}}		}}
	'''Parexel International''' is an American provider of biopharmaceutical services. It conducts [[clinical trial]]s on behalf of its [[pharmaceutical]] clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling [[Pharmaceutical industry\|biopharmaceuticals]] on the market today.<ref>{{cite web\|url=http://moneyshow.com/articles.asp?aid=tptp072513-41094\|title=MoneyShow.com: TOP PROS' TOP PICKS – Parexel Puts Drugs on Trial\|work=MoneyShow.com\|access-date=2015-09-30\|archive-url=https://web.archive.org/web/20160401232913/http://www.moneyshow.com/articles.asp?aid=tptp072513-41094\|archive-date=2016-04-01\|url-status=dead}}</ref> The company publishes the annual Parexel R&D Statistical Sourcebook,<ref>{{Cite web\|url=http://www.barnettinternational.com/Publications/Parexel-Biopharmaceutical/Statistical-Sourcebook-2014/2015-(eStats)/\|title=PAREXEL Biopharmaceutical Statistical Sourcebook 2014/2015 (eStats)\|accessdate=29 March 2023}}</ref> operates the Parexel-Academy,<ref>{{cite web\|url=http://www.appliedclinicaltrialsonline.com/parexel-academy-adds-programs-students\|title=PAREXEL Academy Adds Programs for Students\|author=Applied Clinical Trials Editorial Staff\|date=13 April 2015}}</ref> and councils all of the top 50 biopharmaceutical and top 30 [[biotechnology]] companies.<ref>[http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjQwNDc3fENoaWxkSUQ9LTF8VHlwZT0z&t=1 Corporate Index] {{dead link\|date=March 2023}}</ref>		'''Parexel International''' is an American provider of biopharmaceutical services. It conducts [[clinical trial]]s on behalf of its [[pharmaceutical]] clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling [[Pharmaceutical industry\|biopharmaceuticals]] on the market today.<ref>{{cite web\|url=http://moneyshow.com/articles.asp?aid=tptp072513-41094\|title=MoneyShow.com: TOP PROS' TOP PICKS – Parexel Puts Drugs on Trial\|work=MoneyShow.com\|access-date=2015-09-30\|archive-url=https://web.archive.org/web/20160401232913/http://www.moneyshow.com/articles.asp?aid=tptp072513-41094\|archive-date=2016-04-01\|url-status=dead}}</ref> The company publishes the annual Parexel R&D Statistical Sourcebook<ref>{{Cite web\|url=http://www.barnettinternational.com/Publications/Parexel-Biopharmaceutical/Statistical-Sourcebook-2014/2015-(eStats)/\|title=PAREXEL Biopharmaceutical Statistical Sourcebook 2014/2015 (eStats)\|accessdate=29 March 2023}}</ref> and operates the Parexel-Academy.<ref>{{cite web\|url=http://www.appliedclinicaltrialsonline.com/parexel-academy-adds-programs-students\|title=PAREXEL Academy Adds Programs for Students\|author=Applied Clinical Trials Editorial Staff\|date=13 April 2015}}</ref>

	Parexel was founded in 1982 by Josef von Rickenbach<ref>{{cite web\|url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=209362&ticker=PRXL\|title=List of Public Companies Worldwide, Letter – Businessweek – Businessweek\|work=Businessweek.com\|date=30 June 2023 }}</ref> and organic chemist Anne B. Sayigh<ref>{{Cite web\|url=http://www.the-scientist.com/?articles.view/articleNo/9750/title/Entrepreneur-Briefs/\|title = Entrepreneur Briefs}}</ref> initially to advise Japanese and German firms on how to navigate the [[FDA]] approval process.<ref name="bilanz.ch">{{cite web\|url=http://www.bilanz.ch/people/josef-von-rickenbach-parexel\|title=Josef von Rickenbach – Parexel\|work=Bilanz.ch}}</ref> The firm has grown organically over the years and through 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based on the principles he experienced as a researcher at [[Schering-Plough]] in [[Lucerne, Switzerland]], before leaving the company upon retiring in 2018.<ref name="bilanz.ch" />		Parexel was founded in 1982 by Josef von Rickenbach<ref>{{cite web\|url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=209362&ticker=PRXL\|title=List of Public Companies Worldwide, Letter – Businessweek – Businessweek\|work=Businessweek.com\|date=30 June 2023 }}</ref> and organic chemist Anne B. Sayigh<ref>{{Cite web\|url=http://www.the-scientist.com/?articles.view/articleNo/9750/title/Entrepreneur-Briefs/\|title = Entrepreneur Briefs}}</ref> initially to advise Japanese and German firms on how to navigate the [[FDA]] approval process.<ref name="bilanz.ch">{{cite web\|url=http://www.bilanz.ch/people/josef-von-rickenbach-parexel\|title=Josef von Rickenbach – Parexel\|work=Bilanz.ch}}</ref> The firm has grown organically over the years and through 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based on the principles he experienced as a researcher at [[Schering-Plough]] in [[Lucerne, Switzerland]], before leaving the company upon retiring in 2018.<ref name="bilanz.ch" />

Fostera12: /* Acquisition history */

2023-11-23T04:00:10Z

Acquisition history

← Previous revision		Revision as of 04:00, 23 November 2023
Line 67:		Line 67:
	* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>		* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>
	* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />		* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />
	* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[~~Calyx~~ AI]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>		* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[CALYX (Company)\|CALYX]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>
	* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />		* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />

Fostera12: clean up

2023-11-23T03:55:45Z

clean up

← Previous revision		Revision as of 03:55, 23 November 2023
Line 67:		Line 67:
	* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>		* February 2020: Parexel acquires Model Answers, a consultancy firm based in [[Brisbane]], [[Queensland]], [[Australia]].<ref>{{Cite web\|title=Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers\|url=https://www.parexel.com/news-events-resources/news/current/parexel-announces-acquisition-leading-pharmacology-modeling-analytics-modeling-firm-model-answers\|access-date=2021-06-10\|website=www.parexel.com\|language=en}}</ref>
	* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />		* July 2021: Parexel is acquired by EQT IX fund and the Private Equity business within [[Goldman Sachs]] Asset Management from Pamplona Capital Management LP for $8.5 billion.<ref name=":0" />
	* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, ''Calyx'', a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>~~{{Primary source inline\|date=June 2023}}~~		* January 2021: Following the strategic separation of the Parexel Informatics business from Parexel International, a spin-off, [[Calyx AI]], a provider of medical imaging, eClinical and regulatory solutions and services to solve complex challenges in clinical research, is launched as an independent company.<ref>{{Cite web\|url=https://www.calyx.ai/journal/announcing-calyx-advancing-clinical-research/\|title=Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services\|accessdate=29 March 2023}}</ref>
	* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />		* November 2021: EQT and Goldman Sachs completed the acquisition of Parexel on November 15, 2021.<ref name=":1" />

← Previous revision		Revision as of 22:18, 2 November 2024
Line 43:		Line 43:
	**''LOGOS GmbH'', a provider of regulatory services to pharmaceutical manufacturers, for $3.9 million in own common stock.<ref>{{Cite news\|url=https://www.wsj.com/articles/SB8888824026187500\|title=Parexel Pays $148 Million For Three European Firms\|last=Bulkeley\|first=William M.\|date=1998-03-03\|newspaper=[[The Wall Street Journal]]\|issn=0099-9660\|access-date=2016-12-25}}</ref>		**''LOGOS GmbH'', a provider of regulatory services to pharmaceutical manufacturers, for $3.9 million in own common stock.<ref>{{Cite news\|url=https://www.wsj.com/articles/SB8888824026187500\|title=Parexel Pays $148 Million For Three European Firms\|last=Bulkeley\|first=William M.\|date=1998-03-03\|newspaper=[[The Wall Street Journal]]\|issn=0099-9660\|access-date=2016-12-25}}</ref>
	* March 1999: Parexel acquires ''Groupe PharMedicom S.A.'', a French provider of post-regulatory services to pharmaceutical manufacturers, based in [[Paris]] and [[Orléans]] and employing approximately 70 people, in exchange for approximately 199,600 shares of the company's common stock.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-groupe-pharmedicom-73816747.html\|title=PAREXEL Acquires Groupe Pharmedicom\|date=1999-04-01\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>		* March 1999: Parexel acquires ''Groupe PharMedicom S.A.'', a French provider of post-regulatory services to pharmaceutical manufacturers, based in [[Paris]] and [[Orléans]] and employing approximately 70 people, in exchange for approximately 199,600 shares of the company's common stock.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-groupe-pharmedicom-73816747.html\|title=PAREXEL Acquires Groupe Pharmedicom\|date=1999-04-01\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>
	* April 1999: [[~~Covance Inc.~~]] announced it would acquire ~~its competitor~~ Parexel for $612.7 million in stock ~~and combine the two drug research and development companies under the name ''Covance Parexel Inc.'',~~<ref>{{Cite ~~web~~\|url=https://www.nytimes.com/1999/04/30/business/company-news-covance-says-it-is-acquiring-parexel-for-612-million.html\|title=COVANCE SAYS IT IS ACQUIRING PAREXEL FOR $612 MILLION\|~~date=1999-04-30\|website~~=[[The New York Times]]\|~~access-~~date=~~2016-12~~-25}}</ref> ~~only to call off~~ the agreement two months later.<ref>{{Cite web\|url=https://money.cnn.com/1999/06/25/deals/covance/\|title=Covance, Parexel part\|date=1999-06-25\|website=[[CNNMoney]]\|access-date=2016-12-25}}</ref>		* April 1999: Covance (now [[Fortea]]) announced it would acquire Parexel for $612.7 million in stock;<ref>{{Cite news \|url=https://www.nytimes.com/1999/04/30/business/company-news-covance-says-it-is-acquiring-parexel-for-612-million.html\|title=COVANCE SAYS IT IS ACQUIRING PAREXEL FOR $612 MILLION \|work=[[The New York Times]] \|date=April 30, 1999 \| url-access=limited}}</ref> however, the agreement was terminated two months later.<ref>{{Cite web\|url=https://money.cnn.com/1999/06/25/deals/covance/\|title=Covance, Parexel part\|date=1999-06-25\|website=[[CNNMoney]]\|access-date=2016-12-25}}</ref>
	* September 1999: Parexel acquires ''CEMAF S.A.'', a Phase I clinical research and bioanalytical laboratory located in [[Poitiers, France]] for an initial cash payment of approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-the-phase-i-clinical-research-business-and-bioanalytical-laboratory-of-cemaf-sa-74407922.html\|title=PAREXEL Acquires the Phase I Clinical Research Business And Bioanalytical Laboratory of CEMAF S.A.\|date=1999-09-15\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>		* September 1999: Parexel acquires ''CEMAF S.A.'', a Phase I clinical research and bioanalytical laboratory located in [[Poitiers, France]] for an initial cash payment of approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-the-phase-i-clinical-research-business-and-bioanalytical-laboratory-of-cemaf-sa-74407922.html\|title=PAREXEL Acquires the Phase I Clinical Research Business And Bioanalytical Laboratory of CEMAF S.A.\|date=1999-09-15\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref>
	* September 2000: Parexel acquires a majority interest in ''FARMOVS'', a clinical pharmacology research business and bioanalytical laboratory located in [[Bloemfontein, South Africa]] for approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-majority-interest-in-clinical-pharmacology-research-business-and-bioanalytical-laboratory-in-south-africa-74981577.html\|title=PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa\|date=2000-10-16\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref> A few weeks later the company acquired a clinical pharmacology unit located in [[Northwick Park Hospital]] in [[Harrow (UK Parliament constituency)\|Harrow, U.K.]] from British pharmaceutical company [[GlaxoWellcome Inc.]]<ref>{{Cite web\|url=http://www.drugdiscoveryonline.com/doc/parexel-acquires-glaxos-uk-pharmacology-unit-0001\|title=Parexel acquires Glaxo's UK pharmacology unit\|date=2000-10-04\|website=www.drugdiscoveryonline.com\|access-date=2016-12-25}}</ref>		* September 2000: Parexel acquires a majority interest in ''FARMOVS'', a clinical pharmacology research business and bioanalytical laboratory located in [[Bloemfontein, South Africa]] for approximately $3.0 million.<ref>{{Cite web\|url=http://www.prnewswire.com/news-releases/parexel-acquires-majority-interest-in-clinical-pharmacology-research-business-and-bioanalytical-laboratory-in-south-africa-74981577.html\|title=PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa\|date=2000-10-16\|website=[[PRNewswire]]\|publisher=PAREXEL\|access-date=2016-12-25}}</ref> A few weeks later the company acquired a clinical pharmacology unit located in [[Northwick Park Hospital]] in [[Harrow (UK Parliament constituency)\|Harrow, U.K.]] from British pharmaceutical company [[GlaxoWellcome Inc.]]<ref>{{Cite web\|url=http://www.drugdiscoveryonline.com/doc/parexel-acquires-glaxos-uk-pharmacology-unit-0001\|title=Parexel acquires Glaxo's UK pharmacology unit\|date=2000-10-04\|website=www.drugdiscoveryonline.com\|access-date=2016-12-25}}</ref>

← Previous revision		Revision as of 11:01, 12 February 2024
Line 50:		Line 50:
	* January 2003: Parexel acquires ''FWPS Group Limited'', a provider of software for clinical trial management systems in [[Birmingham, UK]], for approximately $11.9 million in cash and shares.<ref name="Form10k_2003">{{cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013503004856/b47766pie10vk.txt\|title=ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES\|date=2003-09-15\|website=PAREXEL Form 10-K (2003)\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>		* January 2003: Parexel acquires ''FWPS Group Limited'', a provider of software for clinical trial management systems in [[Birmingham, UK]], for approximately $11.9 million in cash and shares.<ref name="Form10k_2003">{{cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013503004856/b47766pie10vk.txt\|title=ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES\|date=2003-09-15\|website=PAREXEL Form 10-K (2003)\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>
	* March 2004: Parexel buys the remaining majority of outstanding shares of ''3Clinical Research AG'', a clinical research organization with expertise in Phase I and Phase IIa Proof-Of-Concept studies in [[Berlin, Germany]], for $11.7 million in cash.<ref name="Form10k_2005">{{Cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013505005299/b55585pie10vk.txt\|title=NOTE 18. SUBSEQUENT EVENTS\|date=2005-09-08\|website=Parexel Form 10-K 2005\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>		* March 2004: Parexel buys the remaining majority of outstanding shares of ''3Clinical Research AG'', a clinical research organization with expertise in Phase I and Phase IIa Proof-Of-Concept studies in [[Berlin, Germany]], for $11.7 million in cash.<ref name="Form10k_2005">{{Cite web\|url=https://www.sec.gov/Archives/edgar/data/799729/000095013505005299/b55585pie10vk.txt\|title=NOTE 18. SUBSEQUENT EVENTS\|date=2005-09-08\|website=Parexel Form 10-K 2005\|publisher=[[EDGAR]]\|access-date=2016-12-25}}</ref>
	* October 2004: Parexel acquires ''Integrated Marketing Concepts'' (IMC), a privately held company based in [[Whitehall Township, Pennsylvania\|Whitehall, PA]], provider of professional marketing and communication services specialized in clinical trial [[patient recruitment]] and retention, sales lead management, teleservices, call center services, fulfillment, focus group and database management, and market research.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2004/10/parexel-acquires-marketing-firm.html\|title=Parexel acquires marketing firm\|date=2004-10-04\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>		* October 2004: Parexel acquires ''Integrated Marketing Concepts'' (IMC), a privately held company based in [[Whitehall Township, Pennsylvania\|Whitehall, PA]], provider of professional marketing and communication services specialized in clinical trial [[patient recruitment]] and retention, sales [[lead management]], teleservices, call center services, fulfillment, focus group and database management, and market research.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2004/10/parexel-acquires-marketing-firm.html\|title=Parexel acquires marketing firm\|date=2004-10-04\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>
	* July 2005: Parexel acquires ''Qdot Pharma'', a Phase I and IIa Proof of Concept clinical pharmacology business located in [[George, South Africa]] for approximately $3.0 million plus additional payments of up to approximately $3.0 million in contingent purchase price if Qdot achieves certain established financial targets through September 28, 2008.<ref name="Form10k_2005" />		* July 2005: Parexel acquires ''Qdot Pharma'', a Phase I and IIa Proof of Concept clinical pharmacology business located in [[George, South Africa]] for approximately $3.0 million plus additional payments of up to approximately $3.0 million in contingent purchase price if Qdot achieves certain established financial targets through September 28, 2008.<ref name="Form10k_2005" />
	* August 2005: Parexel buys the remaining 2.2% of its information technology subsidiary ''Perceptive Informatics Inc.'', for $4.8 million in cash.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2005/08/parexel-buys-out-remaining-minority-interest.html\|title=Parexel buys out remaining minority interest in Perceptive Informatics\|date=2005-08-22\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>		* August 2005: Parexel buys the remaining 2.2% of its information technology subsidiary ''Perceptive Informatics Inc.'', for $4.8 million in cash.<ref>{{Cite web\|url=http://www.bizjournals.com/boston/blog/mass-high-tech/2005/08/parexel-buys-out-remaining-minority-interest.html\|title=Parexel buys out remaining minority interest in Perceptive Informatics\|date=2005-08-22\|website=[[Boston Business Journal]]\|publisher=[[American City Business Journals]]\|access-date=2016-12-25}}</ref>